International Edition
Latest News
Health

New Blood Test Accurately Detects Advanced Tau Pathology in Alzheimer’s Disease

At the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston and online November 16 in JAMA, researchers reported that a new ultrasensitive blood test measuring endogenously cleaved microtubule-binding region tau (eMTBR-tau) accurately identified advanced tau pathology in…

New Blood Test Accurately Detects Advanced Tau Pathology in Alzheimer's Disease

At the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston and online November 16 in JAMA, researchers reported that a new ultrasensitive blood test measuring endogenously cleaved microtubule-binding region tau (eMTBR-tau) accurately identified advanced tau pathology in the brain and performed comparably to mass spectrometry methods.

The plasma immunoassay, developed with Alamar Biosciences, requires just 35 microliters of blood compared with 1.5 milliliters for mass spectrometry, potentially enabling decentralized research and remote collection, Medscape reported. Across two U.S. autopsy cohorts totaling 521 brain donors, eMTBR-tau concentrations rose sharply with advancing neurofibrillary tangle pathology, particularly at Braak stages V and VI. At Braak stage VI, levels were 50.5-fold and 25.2-fold higher than at stages I-II (P < .001 for both), while corresponding increases for phosphorylated tau 217 (p-tau217) were 4.6-fold and 3.2-fold.

In one autopsy cohort, eMTBR-tau distinguished advanced from earlier Braak stages with an area under the curve (AUC) of 0.93 versus 0.84 for p-tau217 (P < .001); the difference was not statistically significant after adjustment in the second cohort. Two tau-PET imaging cohorts reinforced the results: in the 99-participant TRIAD cohort, eMTBR-tau concentrations were nearly 60-fold higher at tau-PET Braak stages V-VI than at stage 0, compared with a 4.9-fold increase for p-tau217. In the BioFINDER-2 cohort, the immunoassay showed strong agreement with mass spectrometry (correlation coefficient 0.93 overall, 0.96 among amyloid-positive participants), with both methods identifying regional tau-PET positivity with AUCs of 0.96–0.99.

“Late-stage tau that we’re detecting through this biomarker,” said Nicholas Ashton, PhD, senior director of Banner’s Fluid Biomarker Program at Banner Sun Health Research Institute in Sun City, Arizona. “I still think we’re missing that sensitivity, or maybe missing that novel biomarker for the earlier [Braak] stage regions.”

“One of the most challenging tasks in Alzheimer’s disease diagnosis is to establish in a patient with cognitive impairment that Alzheimer’s pathology is not just present, but that is present in a sufficiently advanced biological stage to be a likely explanation for symptoms,” said Dr. Niklas Mattsson-Carlgren of Lund University in Sweden, CTV News reported.

The test is not yet available for clinical use and is not meant to diagnose Alzheimer’s on its own, the researchers said. Current blood tests measure proteins such as beta-amyloid and phosphorylated tau that rise early but give limited information about tau tangle buildup in later stages, while two approved drugs target amyloid plaques and several in development target tau.

“Having a simple yet highly scalable way to determine the extent of tau tangle buildup in the brain represents a major step forward in our understanding of Alzheimer’s,” Ashton said. Together, existing blood tests and the new eMTBR-tau test could help doctors make better treatment decisions and identify the right patients for clinical trials, he added.

Alamar Biosciences, the precision proteomics company that co-developed the eMTBR-tau immunoassay, was founded in 2018 in Fremont, California. The company closed an $80 million Series B round in September 2021, bringing total funding to $110 million, and listed on NASDAQ under the ticker ALMR in April 2026 with a market capitalization of approximately $1.5 billion.

Its proprietary NULISA™ platform achieves single-digit attomolar sensitivity and, as of late 2025, the ARGO™ HT automated system had an installed base of over 100 instruments serving more than 300 customers across 25 countries.

The investigators acknowledged limitations including the cross-sectional design, relatively small imaging cohorts, limited racial and ethnic diversity, and many early Braak-stage values below the assay’s lower limit of quantification. Larger prospective studies are needed to establish clinical cutoffs, determine whether the test predicts cognitive decline or treatment response, and validate performance across laboratories.

About the author: Health Desk

Health Desk at Archynewsy.